Eton Pharmaceuticals Inc (ETON) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

Adds an additional commercial and strategic rare disease product to Eton’s portfolioGalzin is FDA-approved for...

Form 8-K - Current report

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Acquisition bolsters Eton’s commercial pediatric endocrinology portfolioProduct is now available through...

Form 8-K - Current report

Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial

DEER PARK, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her...

Form 8-K - Current report